Advertisement

Die BCG-Perfusion des oberen Harntraktes

  • V. W. Merz
  • G. Thalmann
  • D. K. Ackermann
  • U. E. Studer
Conference paper

Zusammenfassung

Die intravesikale Applikation von Bacillus Calmette-Guérin (BCG) ist eine wirksame und anerkannte Therapie des Carcinoma in situ der Harnblase (Brosman 1982; Herr et al. 1983; Lamm 1985; deKernion et al. 1985; Catalonaet al. 1987; Ackermannet al. 1986). Obwohl Patienten mit Carcinoma in situ der Harnblase seit 1976 mit BCG behandelt werden, verbleibt der Wirkmechanismus ungeklärt. Der direkte Kontakt von BCG mit dem befallenen Urothel scheint äußerst wichtig zu sein. Die Persistenz von Carcinoma in situ im distalen Ureter oder in der prostatischen Harnröhre nach der erfolgreichen Behandlung des Cis in der Harnblase durch BCG-Instillationen spricht für einen primären topischen Effekt, welcher nur entsteht, wenn das BCG direkt mit dem Urothel in Beziehung tritt (Herr u. Whitmore 1987; Herr et al. 1986; Studer et al. 1987). Dem Fibronectin, einem dimeren Glykoprotein der Zelladhäsion, kommt in diesem Zusammenhang eine wesentliche Rolle zu (Ratliff et al. 1987).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ackermann D, Schnyder M, Bandelier D, Studer UE (1986) Traitement des tumeurs superficielles de la vessie par le bacillus de Calmette-Guérin (BCG). J Urol (Paris) 92: 33–38Google Scholar
  2. Brosman SA (1982) Experience with Bacillus Calmette-Guérin in patients with superficial bladder carcinoma. J Urol 128: 27–30PubMedGoogle Scholar
  3. Catalona WJ, Hudson MA, Gillen DP, Andriole GL, Ratliff TL (1987) Risks and benefits of repeated courses of intravesical Bacillus Calmette-Guérin therapy for superficial bladder cancer. J Urol 137: 220–224PubMedGoogle Scholar
  4. deKernion JB, Huang M-Y, Lindner A, Smith RB, Kaufman JJ (1985) The management of superficial bladder tumors and carcinoma in situ with intravesical Bacillus Calmette-Guérin. J Urol 133: 598–601PubMedGoogle Scholar
  5. Droller MJ (1986) Bacillus Calmette-Guérin in the management of bladder cancer (Editorial). J Urol 135: 331–333PubMedGoogle Scholar
  6. Herr HW (1985) Durable response of a carcinoma in situ of the renal pelvis to topical Bacillus Calmette-Guérin. J Urol 134: 531–532PubMedGoogle Scholar
  7. Herr HW, Whitmore WF Jr (1987) Ureteral carcinoma in situ after successful intravesical therapy for superficial bladder tumors: incidence, possible pathogenesis and management. J Urol 138: 292–294PubMedGoogle Scholar
  8. Herr HW, Pinsky CM, Whitmore WF Jr, Oettgen HF, Melamed MR (1983) Effect of intravesical Bacillus Calmette-Guérin (BCG) on carcinoma in situ of the bladder. Cancer 51:1323–1326PubMedCrossRefGoogle Scholar
  9. Herr HW, Pinsky CM, Whitmore WF Jr, Sogani PC, Oettgen HF, Melamed MR (1986) Long-term effect of intravesical Bacillus Calmette-Guérin on flat carcinoma in situ of the bladder. J Urol 135: 265–267PubMedGoogle Scholar
  10. Lamm DL (1985) Bacillus Calmette-Guérin immunotherapy for bladder cancer. J Urol 134: 40–47PubMedGoogle Scholar
  11. Ratliff TL, Gillen D (1986) Requirement for thymus-dependent immune response for the inhibition of intravesical mouse bladder tumor growth. J Urol 135:122AGoogle Scholar
  12. Ratliff TL, Palmer JO, McGarr JA, Brown EJ (1987) Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin. Cancer Res 47: 1762–1766PubMedGoogle Scholar
  13. Schellhammer PF (1987) Letter to the Editor. Re: Intravesical Bacillus Calmette-Guérin therapy and associated granulomatous renal masses. Stanisic et al. J Urol 137: 315PubMedGoogle Scholar
  14. Shapiro A, Ratliff TL, Oakley DM, Catalona WJ (1983) Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guérin and its correlation with Bacillus Calmette-Guérin viability and natural killer cell activity. Cancer Res 43: 1611–161PubMedGoogle Scholar
  15. Studer UE, Ackermann D, Schnyder V, Wartensee M (1987) Immunotherapie bei oberflächlichen Harnblasentumoren. In: Sommerkamp H, Altwein JE, Klippel KF (Hrsg) Urologische Onkologie I. Zuckschwerdt, München Bern Wien San Francisco, pp 129–135Google Scholar
  16. Stanisic TH, Brewer ML, Graham AR (1986) Intravesical Bacillus Calmette- Guérin therapy and associated granulomatous renal masses. J Urol 135: 356–358PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • V. W. Merz
  • G. Thalmann
  • D. K. Ackermann
  • U. E. Studer
    • 1
  1. 1.Urologische UniversitätsklinikInselspitalBernSwitzerland

Personalised recommendations